333 related articles for article (PubMed ID: 35997941)
1. Antithrombotic Therapy for Symptomatic Peripheral Arterial Disease: A Systematic Review and Network Meta-Analysis.
Willems LH; Maas DPMSM; Kramers K; Reijnen MMPJ; Riksen NP; Ten Cate H; van der Vijver-Coppen RJ; de Borst GJ; Mees BME; Zeebregts CJ; Hannink G; Warlé MC
Drugs; 2022 Aug; 82(12):1287-1302. PubMed ID: 35997941
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic Efficacy and Safety of Antithrombotic Regimens in Patients with Stable Atherosclerotic Cardiovascular Disease (S-ASCVD): A Bayesian Network Meta-Regression Analysis.
Zheng N; Zhong J; Chen X; Su J; Liu C; Jiang L
Am J Cardiovasc Drugs; 2023 May; 23(3):257-267. PubMed ID: 36867384
[TBL] [Abstract][Full Text] [Related]
3. Antithrombotic treatment in peripheral artery disease.
Olinic DM; Tataru DA; Homorodean C; Spinu M; Olinic M
Vasa; 2018 Feb; 47(2):99-108. PubMed ID: 29160765
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Different Chronic Maintenance Antithrombotic Strategies in Patients with Coronary Artery Disease: A Systematic Review and Network Meta-Analysis.
Zhang J; Chen Z; Cai Y; Li C; He Y
Cardiovasc Ther; 2023; 2023():5446271. PubMed ID: 37636560
[TBL] [Abstract][Full Text] [Related]
5. Do we have a unified consensus on antithrombotic management of PAD?
Poredos P; Antignani PL; Blinc A; Fras Z; Jezovnik MK; Fareed J; Mansilha A
Int Angiol; 2021 Jun; 40(3):229-239. PubMed ID: 33739074
[TBL] [Abstract][Full Text] [Related]
6. Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment.
Robertson L; Ghouri MA; Kovacs F
Cochrane Database Syst Rev; 2012 Aug; 2012(8):CD002071. PubMed ID: 22895926
[TBL] [Abstract][Full Text] [Related]
7. Rivaroxaban Plus Aspirin Versus Aspirin Alone After Endovascular Revascularization for Symptomatic PAD: Insights From VOYAGER PAD.
Rymer J; Anand SS; Sebastian Debus E; Haskell LP; Hess CN; Jones WS; Muehlhofer E; Berkowitz SD; Bauersachs RM; Bonaca MP; Patel MR
Circulation; 2023 Dec; 148(24):1919-1928. PubMed ID: 37850397
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Rivaroxaban Compared with Other Therapies Used in Patients with Peripheral Artery Disease Undergoing Peripheral Revascularization: A Systematic Literature Review and Network Meta-Analysis.
Bauersachs R; Wu O; Hawkins N; Bowrin K; Wojciechowski P; Clay E; Huelsebeck M
Cardiovasc Ther; 2021; 2021():8561350. PubMed ID: 34497668
[TBL] [Abstract][Full Text] [Related]
9. Comparative Efficacy and Safety of Different Antiplatelet Agents for Prevention of Major Cardiovascular Events and Leg Amputations in Patients with Peripheral Arterial Disease: A Systematic Review and Network Meta-Analysis.
Katsanos K; Spiliopoulos S; Saha P; Diamantopoulos A; Karunanithy N; Krokidis M; Modarai B; Karnabatidis D
PLoS One; 2015; 10(8):e0135692. PubMed ID: 26274912
[TBL] [Abstract][Full Text] [Related]
10. Antithrombotic Treatments in Patients with Chronic Coronary Artery Disease or Peripheral Artery Disease: A Systematic Review of Randomised Controlled Trials.
Bauersachs R; Wu O; Briere JB; Bowrin K; Borkowska K; Jakubowska A; Taieb V; Toumi M; Huelsebeck M
Cardiovasc Ther; 2020; 2020():3057168. PubMed ID: 32695228
[TBL] [Abstract][Full Text] [Related]
11. Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial.
Berger JS; Abramson BL; Lopes RD; Heizer G; Rockhold FW; Baumgartner I; Fowkes FGR; Held P; Katona BG; Norgren L; Jones WS; Millegård M; Blomster J; Reist C; Hiatt WR; Patel MR; Mahaffey KW
Vasc Med; 2018 Dec; 23(6):523-530. PubMed ID: 29992857
[TBL] [Abstract][Full Text] [Related]
12. Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization.
Hess CN; Szarek M; Anand SS; Bauersachs RM; Patel MR; Debus ES; Nehler MR; Capell WH; Beckman JA; Piazza G; Henkin S; Bura-Rivière A; Lawall H; Roztocil K; Hsia J; Muehlhofer E; Berkowitz SD; Haskell LP; Bonaca MP
JAMA Netw Open; 2022 Jun; 5(6):e2215580. PubMed ID: 35731517
[TBL] [Abstract][Full Text] [Related]
13. Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and Safety.
Hiatt WR; Bonaca MP; Patel MR; Nehler MR; Debus ES; Anand SS; Capell WH; Brackin T; Jaeger N; Hess CN; Pap AF; Berkowitz SD; Muehlhofer E; Haskell L; Brasil D; Madaric J; Sillesen H; Szalay D; Bauersachs R
Circulation; 2020 Dec; 142(23):2219-2230. PubMed ID: 33138628
[TBL] [Abstract][Full Text] [Related]
14. Comparison of rivaroxaban-based dual antithrombotic and antiplatelet therapies for symptomatic patients with lower-extremity peripheral artery disease post-revascularization: a retrospective cohort study.
Ji Y; Wang B; Wu G; Zhang Y; Wang Q; Zhou M
Ther Adv Chronic Dis; 2023; 14():20406223231213262. PubMed ID: 38085917
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland.
Soini E; Virtanen O; Väätäinen S; Briere JB; Bowrin K; Millier A
Adv Ther; 2020 Jul; 37(7):3348-3369. PubMed ID: 32519113
[TBL] [Abstract][Full Text] [Related]
16. Within and beyond 12-month efficacy and safety of antithrombotic strategies in patients with established coronary artery disease: two companion network meta-analyses of the 2022 joint clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Association for Acute CardioVascular Care (ACVC), and European Association of Preventive Cardiology (EAPC).
Navarese EP; Landi A; Oliva A; Piccolo R; Aboyans V; Angiolillo D; Atar D; Capodanno D; Fox KAA; Halvorsen S; James S; Jüni P; Kunadian V; Leonardi S; Mehran R; Montalescot G; Niebauer J; Price S; Storey RF; Völler H; Vranckx P; Windecker S; Valgimigli M
Eur Heart J Cardiovasc Pharmacother; 2023 Apr; 9(3):271-290. PubMed ID: 36869784
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Antiplatelet Therapies in Symptomatic Peripheral Artery Disease: A Systematic Review and Network Meta-Analysis.
De Carlo M; Di Minno G; Sayre T; Fazeli MS; Siliman G; Cimminiello C
Curr Vasc Pharmacol; 2021; 19(5):542-555. PubMed ID: 32819249
[TBL] [Abstract][Full Text] [Related]
18. Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials.
Anand SS; Hiatt W; Dyal L; Bauersachs R; Berkowitz SD; Branch KRH; Debus S; Fox KAA; Liang Y; Muehlhofer E; Nehler M; Haskell LP; Patel M; Szarek M; Yusuf S; Eikelboom J; Bonaca MP
Eur J Prev Cardiol; 2022 May; 29(5):e181-e189. PubMed ID: 34463737
[TBL] [Abstract][Full Text] [Related]
19. Comparison efficacy and safety of different antiplatelet or anticoagulation drugs in chronic coronary syndromes patients: A Bayesian network meta-analysis.
Liu C; Ma L
Medicine (Baltimore); 2023 Dec; 102(48):e36429. PubMed ID: 38050293
[TBL] [Abstract][Full Text] [Related]
20. Antiplatelet therapy with or without anticoagulant therapy for lower extremity peripheral artery disease: A systematic review.
Rahmatian D; Barry AR
Am J Health Syst Pharm; 2021 Nov; 78(23):2132-2141. PubMed ID: 34059879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
